The Journal of Experimental Medicine
Rockland Immunochemicals for Research
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 21 July 2003. doi:10.1084/jem.20021924
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 200K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lapenta, C.
Right arrow Articles by Belardelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lapenta, C.
Right arrow Articles by Belardelli, F.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*AIDS
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2003/7/361 $5.00
The Journal of Experimental Medicine, Volume 198, Number 2, 361-367


Brief Definitive Report

Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-{alpha}

Caterina Lapenta, Stefano M. Santini, Mariantonia Logozzi, Massimo Spada, Mauro Andreotti, Tiziana Di Pucchio, Stefania Parlato and Filippo Belardelli

Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy 00161

Address correspondence to Filippo Belardelli, Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena, 299, Rome, Italy 00161. Phone: 39-06-4990-3290; Fax: 39-06-4990-2097; E-mail: belard{at}iss.it

A major challenge of AIDS research is the development of therapeutic vaccine strategies capable of inducing the humoral and cellular arms of the immune responses against HIV-1. In this work, we evaluated the capability of DCs pulsed with aldrithiol-2–inactivated HIV-1 in inducing a protective antiviral human immune response in SCID mice reconstituted with human PBL (hu-PBL-SCID mice). Immunization of hu-PBL-SCID mice with DCs generated after exposure of monocytes to GM-CSF/IFN-{alpha} (IFN-DCs) and pulsed with inactivated HIV-1 resulted in a marked induction of human anti–HIV-1 antibodies, which was associated with the detection of anti-HIV neutralizing activity in the serum. This vaccination schedule also promoted the generation of a human CD8+ T cell response against HIV-1, as measured by IFN-{gamma} Elispot analysis. Notably, when the hu-PBL-SCID mice immunized with antigen-pulsed IFN-DCs were infected with HIV-1, inhibition of virus infection was observed as compared with control animals. These results suggest that IFN-DCs pulsed with inactivated HIV-1 can represent a valuable approach of immune intervention in HIV-1–infected patients.

Key Words: antigen presenting cell • vaccine • neutralizing antibodies • CD8+ T lymphocytes • AIDS


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS